Australia TGA ARTG recorde.p.t.q. Lidocaine S500 - Synthetic-fluid tissue reconstructive material, anaesthetic
Australia TGA ARTG Registered Device · Xytide Biotech Pty Ltd · Jetema Co Ltd · Class III · Started February 22, 2024
Good Name: Xytide Biotech Pty Ltd - e.p.t.q. Lidocaine S500 - Synthetic-fluid tissue reconstructive material, anaesthetic
- Risk Class
- Class III
- Product Type
- Single Device Product
- ARTG Category
- General
- Start Date
- February 22, 2024
- Effective Date
- February 22, 2024
- Name
- Jetema Co Ltd
- Country
- South Korea
- Address
- 16-25 Dongbaekjungang-ro 16beon-gil Giheung-gu, Yongin-si, Gyeonggi-do
e.p.t.q. Lidocaine (S500) is intended to be used for the correction of nasolabial folds. The product is for cosmetic use only. The addition of lidocaine provides a pain-relieving effect during treatment.
Access comprehensive regulatory information for e.p.t.q. Lidocaine S500 - Synthetic-fluid tissue reconstructive material, anaesthetic in the Australia medical device market through Pure Global AI's free TGA ARTG database. This Class III is sponsored by Xytide Biotech Pty Ltd, manufactured by Jetema Co Ltd in South Korea. The device registration started on February 22, 2024.
This page provides complete registration details including sponsor information, manufacturer details, and regulatory compliance data from the official Australia TGA ARTG medical device database. Pure Global AI offers free access to Australia's complete medical device registry with 131,000+ devices, helping global MedTech companies navigate TGA regulations efficiently.